Particularly, inform your doctor or pharmacist if you are taking any of the following medications:
- Ritonavir, saquinavir (used to treat HIV).
- Quinidine (used to treat abnormal heart rhythms).
- Desmopressin oral (used to treat central diabetes insipidus and nocturnal urinary incontinence in children).
- Itraconazole (used to treat fungal infections).
- Ketoconazole (used to treat Cushing's syndrome)
- Gemfibrozil (used to lower cholesterol).
- St. John's Wort (used to improve mood states).
- Valerian (used to treat mild anxiety).
- Opioid analgesics (used to treat very intense pain) as Lopestop may increase the risk of severe constipation and central nervous system depression (e.g., drowsiness or decreased consciousness).
- Broad-spectrum antibiotics as Lopestop may worsen or prolong diarrhea caused by antibiotics.
Lopestop may increase the effect of medications with similar properties.
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before taking this medication.
Pregnancy
The safety of use of this medication during pregnancy has not been established, so pregnant women should not take this medication unless prescribed by a doctor.
Breastfeeding
Loperamide should not be used by women who are breastfeeding as small amounts of this medication may pass into breast milk.
Driving and operating machinery
If drowsiness, dizziness, or somnolence appears during treatment of diarrhea with Lopestop, it is best not to use machinery or drive vehicles.
Follow exactly the administration instructions of this medication contained in this leaflet or those indicated by your doctor or pharmacist. In case of doubt, ask your doctor or pharmacist.
The recommended dose is:
Adults
2 capsules (4 mg) as initial dose, followed by 1 capsule (2 mg) after each diarrheal stool. Do not take more than 8 capsules (16 mg) per day.
Older adolescents (over 12 years)
1 capsule (2 mg) as initial dose, followed by 1 capsule (2 mg) after each diarrheal stool. In children, the maximum daily dose should be related to body weight:
Child weight | Maximum number of capsules per day |
From 27 kg | Maximum 4 capsules |
From 34 kg | Maximum 5 capsules |
From 40 kg | Maximum 6 capsules |
From 47 kg | Maximum 7 capsules |
Patients with liver disease
They should consult their doctor before taking this medication.
Administration form
This medication is administered orally.
The capsules should be taken with a full glass of water.
Do not exceed the recommended dose.
If you estimate that Lopestop's action is too strong or too weak, inform your doctor or pharmacist.
If you take more Lopestop than you should
If you have taken too much Lopestop, contact a doctor or hospital as soon as possible to seek help. Symptoms may include: increased heart rate, irregular heartbeats, arrhythmias (these symptoms may have potentially serious and life-threatening consequences), muscle stiffness, uncoordinated movements, drowsiness, difficulty urinating, weak breathing, pupil constriction (miosis), dry mouth, abdominal discomfort, nausea, vomiting, and constipation.
Children react more severely to high amounts of Lopestop than adults. If a child takes an excessive amount or presents any of the above symptoms, call a doctor immediately.
In case of overdose or accidental ingestion, go immediately to a medical center or call the Toxicological Information Service (Telephone 91 562 04 20), indicating the medication and the amount ingested.
If you forgot to take Lopestop
Do not take a double dose to compensate for the missed doses.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
If any of the following side effects appear, stop treatment and consult your doctor:
Other side effects that may appear are:
Frequent adverse reactions (may affect up to 1 in 10 patients):
Rare adverse reactions (may affect up to 1 in 100 patients):
In rare cases (may affect up to 1 in 1,000 patients):
Unknown frequency (cannot be estimated from available data)
Upper abdominal pain, abdominal pain radiating to the back, abdominal tenderness, fever, rapid pulse, nausea, vomiting, which may be symptoms of acute pancreatitis.
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
No special storage conditions are required.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Unused medications should not be disposed of through drains or in the trash. Dispose of the packaging of unused medications at your local pharmacy's SIGRE point or ask your pharmacist for guidance on how to dispose of unused packaging and medications. By doing so, you will help protect the environment.
Composition of Lopestop
The active ingredient of Lopestop is: hydrochloride of loperamide. Each capsule contains 2 mg of hydrochloride of loperamide.
The other components (excipients) are: microcrystalline cellulose, talc (E-553b) and magnesium stearate (E-572). The components of the capsule are: gelatin, titanium dioxide (E-171) and iron oxide red (E-172).
Appearance of the product and contents of the packaging
Lopestop is presented in the form of hard gelatin capsules with a red cap and a white body.
Each package of Lopestop contains 10 or 20 hard capsules.
Holder of the marketing authorization
Apotheke Laboratorios, S.L.
Paseo de la Castellana nº 40, 8ª
28046, Madrid (Madrid).
Spain
Phone: +34 91 669 03 45
Email: [email protected]
Responsible for manufacturing
Laboratorio GENERFARMA, S.L.
C/ Isaac Peral 6 – Technological Park
46980 Paterna – Valencia
Phone: +34 96 374 22 12
Fax: +34 96 395 19 82
Email: [email protected]
This leaflet has been approved in: May 2022
The detailed and updated information of this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) https://www.aemps.gob.es
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.